JAMES CITY COUNTY, Va. — CEL Critical Power, a global provider of power solutions, will invest $5.2 million to open its first American manufacturing facility in James City County, Governor Glenn ...

The MarketWatch News Department was not involved in the creation of this content. Phase 1a/1b study will evaluate NRM-823 as monotherapy and in combination with immune checkpoint inhibition in ...

Please provide your email address to receive an email when new articles are posted on . Patients with sickle cell disease and beta-thalassemia reported substantial improvements in quality of life ...

More than a third of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with the CAR T-cell therapy obecabtagene autoleucel (obe-cel) remained in remission at a ...

CEL-SCI Corporation (NYSE:CVM) shares tumbled 38.19% in after-hours trading to $8.06 on Tuesday following the cancer immunotherapy company’s announcement of a $10 million public offering priced below ...

Researchers from Trina Solar and China’s Nanchang University claim to have verified that back-contact solar modules outperform TOPCon modules only when fewer than three cells in a substring are shaded ...

VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the closing of its underwritten ...

The masked anti-Israel rabble-rousers who stormed Columbia University’s library passed out flyers lionizing alleged Palestinian terrorist Bassel al-Araj as a “militant intellectual,” The Post has ...

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (“CEL-SCI” or the “Company”) (NYSE American: CVM), a cancer immunotherapy company, today announced the closing of its previously announced ...

Obecabtagene autoleucel (obe-cel) is an autologous 41BB-ζ anti-CD19 chimeric antigen receptor (CAR) T-cell therapy which uses an intermediate-affinity CAR to reduce toxic effects and improve ...

Patients with relapsed or refractory CD19-positive B-cell acute lymphoblastic leukemia (ALL) who were treated with the novel anti-CD19 chimeric antigen receptor (CAR) T cell therapy, obecabtagene ...

Ayyoun is a staff writer who loves all things gaming and tech. His journey into the realm of gaming began with a PlayStation 1 but he chose PC as his platform of choice. With over 6 years of ...